Paper
Document
Submit new version
Download
Flag content
0

Development and Validation of the Gene Expression Predictor of High-grade Serous Ovarian Carcinoma Molecular SubTYPE (PrOTYPE)

Authors
Aline Talhouk,Joshy George
Chen Wang,Timothy Budden,Tuan Tan,Derek Chiu,Stefan Kommoss,Huei Leong,Stephanie Chen,Maria Intermaggio,C. Gilks,Tayyebeh Nazeran,Mila Volchek,Wafaa Elatre,Rex Bentley,Janine Senz,Amy Lum,Veronica Chow,Hanwei Sudderuddin,Robertson Mackenzie,Samuel Leong,Geyi Liu,D. Johnson,Billy Chen,Gerasimos Aravantinos,Jennifer Alsop,Susana Banerjee,Sabine Behrens,Clara Bodelón,Alison Brand,Louise Brinton,Michael Carney,Yoke-Eng Chiew,Kara Cushing‐Haugen,Cezary Cybulski,Darren Ennis,Sián Fereday,Renée Fortner,Jesús García-Donás,Aleksandra Gentry‐Maharaj,Rosalind Glasspool,Teodora Goranova,Casey Greene,Paul Haluska,Holly Harris,Joy Hendley,Brenda Hernandez,Esther Herpel,Mercedes Jimenez‐Liñan,Chloe Karpinskyj,Scott Kaufmann,Gary Keeney,Catherine Kennedy,Martin Köbel,Jennifer Koziak,Melissa Larson,Jenny Lester,Liz-Anne Lewsley,Jolanta Lissowska,Jan Lubiński,Hugh Luk,Geoff Macintyre,Sven� Mahner,Iain McNeish,Janusz Menkiszak,Nikilyn Nevins,Ana Osório,Oleg Oszurek,José Palacios,Samantha Hinsley,Celeste Pearce,Malcolm Pike,Anna Piskorz,Isabelle Ray‐Coquard,Valerie Rhenius,Cristina Rodríguez‐Antona,Raghwa Sharma,Mark Sherman,Dilrini Silva,Naveena Singh,Hans‐Peter Sinn,Dennis Slamon,Honglin Song,Helen Steed,Euan Stronach,Deborah Thompson,Aleksandra Tołoczko,Britton Trabert,Nadia Traficante,Chiu-Chen Tseng,Martin Widschwendter,Lynne Wilkens,Stacey Winham,Boris Winterhoff,Alicia Beeghly‐Fadiel,Javier Benı́tez,Andrew Berchuck,James Brenton,Robert Brown,Jenny Chang‐Claude,Georgia Chenevix‐Trench,Anna deFazio,Peter Fasching,María García,Simon Gayther,Marc Goodman,Jacek Gronwald,Michelle Henderson,Beth Karlan,Linda Kelemen,Usha Menon,Sandra Oršulić,Paul Pharoah,Nicolas Wentzensen,Anna Wu,Joellen Schildkraut,Mary Rossing,Gottfried Konecny,David Huntsman,Ruby Huang,Ellen Goode,Susan Ramus,Jennifer Doherty,David Bowtell,Michael Anglesio
+123 authors
,Ana Osorio
Published
Oct 15, 2020
Show more
Save
TipTip
Document
Submit new version
Download
Flag content
0
TipTip
Save
Document
Submit new version
Download
Flag content

Abstract

Abstract Purpose: Gene expression–based molecular subtypes of high-grade serous tubo-ovarian cancer (HGSOC), demonstrated across multiple studies, may provide improved stratification for molecularly targeted trials. However, evaluation of clinical utility has been hindered by nonstandardized methods, which are not applicable in a clinical setting. We sought to generate a clinical grade minimal gene set assay for classification of individual tumor specimens into HGSOC subtypes and confirm previously reported subtype-associated features. Experimental Design: Adopting two independent approaches, we derived and internally validated algorithms for subtype prediction using published gene expression data from 1,650 tumors. We applied resulting models to NanoString data on 3,829 HGSOCs from the Ovarian Tumor Tissue Analysis consortium. We further developed, confirmed, and validated a reduced, minimal gene set predictor, with methods suitable for a single-patient setting. Results: Gene expression data were used to derive the predictor of high-grade serous ovarian carcinoma molecular subtype (PrOTYPE) assay. We established a de facto standard as a consensus of two parallel approaches. PrOTYPE subtypes are significantly associated with age, stage, residual disease, tumor-infiltrating lymphocytes, and outcome. The locked-down clinical grade PrOTYPE test includes a model with 55 genes that predicted gene expression subtype with >95% accuracy that was maintained in all analytic and biological validations. Conclusions: We validated the PrOTYPE assay following the Institute of Medicine guidelines for the development of omics-based tests. This fully defined and locked-down clinical grade assay will enable trial design with molecular subtype stratification and allow for objective assessment of the predictive value of HGSOC molecular subtypes in precision medicine applications. See related commentary by McMullen et al., p. 5271

Paper PDF

This paper's license is marked as closed access or non-commercial and cannot be viewed on ResearchHub. Visit the paper's external site.